2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Breast
1
Conditions
Keratosis, Actinic
29
Uterine Cervical Dysplasia
14
Carcinoma, Basal Cell
12
Melanoma
10
Glioma
6
Glioblastoma
6
Breast Neoplasms
5
Uterine Cervical Neoplasms
4
Neoplasm Metastasis
4
Keratosis
4
Condylomata Acuminata
4
Precancerous Conditions
3
Papillomavirus Infections
3
Hutchinson's Melanotic Freckle
3
Vulvar Neoplasms
2
Urinary Bladder Neoplasms
2
Squamous Intraepithelial Lesions
2
Non-Muscle Invasive Bladder Neoplasms
2
Neoplasms
2
Hemangioma, Capillary
2
HIV Infections
2
Ependymoma
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Astrocytoma
2
Warts
1
Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)
1
Virus Diseases
1
Vaginal Neoplasms
1
Stomach Neoplasms
1
Interventions
Oxaliplatin
295
Capecitabine
209
Fluorouracil
183
Cisplatin
172
Docetaxel
140
S 1 (combination)
135
Paclitaxel
128
Leucovorin
117
Irinotecan
110
pembrolizumab
104
Trastuzumab
75
Nivolumab
59
apatinib
57
Drug Therapy
52
sintilimab
46
Surgical Procedures, Operative
45
Ramucirumab
40
Radiotherapy
40
Bevacizumab
37
Hyperthermic Intraperitoneal Chemotherapy
34
Epirubicin
32
titanium silicide
31
tislelizumab
31
Carboplatin
31
Gastrectomy
28
Cyclophosphamide
27
XELOX
25
Tegafur
24
Folfox protocol
23
Albumin-Bound Paclitaxel
23
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
Imiquimod
×
Clear all
NCT02276300
2019-11-20
HER2
Technical University of Munich
Phase 1
Completed
2 enrolled